C. Topham

8.9k citations

37 papers · 6.5k indexed · 3 hit papers · h-index 20

Impact in

Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Cancer Treatment and Pharmacology
- Colorectal Cancer Screening and Detection
Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Oncology 32
- Colorectal Cancer Treatments and Studies 22
- Cancer Treatment and Pharmacology 11
- Colorectal Cancer Surgical Treatments 9
Hepatology 4
- Hepatocellular Carcinoma Treatment and Prognosis 4

Co-authors: Tamas Hickish Matilde Navarro C. Boni Thierry André Josep Tabernero Aimery de Gramont John Bridgewater Philip R. Clingan
Journals: Journal of Clinical Oncology (10 papers)British Journal of Cancer (5 papers)The Lancet (3 papers)International Journal of Oncology (3 papers)Seminars in Oncology (2 papers)
Partner nations: United Kingdom France Spain

In The Last Decade

C. Topham

37 papers receiving 6.4k citations

Hit Papers

align trajectories log scale

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial 2009 · 1.6k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 Journal of Clinical Oncology
2004 New England Journal of Medicine
1998 The Lancet

Peers

Countries citing papers authored by C. Topham

Since Specialization

Citations

This map shows the geographic impact of C. Topham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Topham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Topham more than expected).

Fields of papers citing papers by C. Topham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Topham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Topham. The network helps show where C. Topham may publish in the future.

Co-authors

The 25 scholars most cited alongside C. Topham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C. Topham Line = papers co-authored together C. Topham links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2) British Journal of Cancer ·Simon Gollins, Swe Swe Myint, S. Susnerwala, Brian Haylock, Marcus Wise, C. Topham, Leslie Samuel, R. Swindell, J. A. Martinez, Uli Johannes, Edward A. Levine	2009	19
2	Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial Journal of Clinical Oncology ·Thierry André, C. Boni, Matilde Navarro, Josep Tabernero, Tamas Hickish, C. Topham, Andrea Bonetti, Philip R. Clingan, John Bridgewater, Fernando Rivera, Aimery de Gramont Hit paper breakdown →	2009	1603
3	A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma British Journal of Cancer ·Kakuzi Takahasi, David B. Smith, C. Topham, D. Jackson, Alan Anthoney, Nirmala Trisna, Michel Seymour	2006	11
4	Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients International Journal of Oncology ·Matthew Cunningham, Sharadah Essapen, Hilary Thomas, Margaret Green, David Lovell, C. Topham, George D. Stump, Helmout Modjtahedi	2006	36
5	Once-Weekly Treatment of Anemia in Patients with Cancer: A Comparative Review of Epoetins Oncology ·Éric Pujade-Lauraine, C. Topham	2005	7
6	Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years Journal of Clinical Oncology ·Armand de Gramont, C. Boni, Matilde Navarro, Josep Tabernero, Tamas Hickish, C. Topham, Andrea Bonetti, P. Clingan, George Petridis, Christelle Lorenzato, Thierry André	2005	76
7	Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer International Journal of Oncology ·Matthew Cunningham, Sharadah Essapen, Hilary Thomas, Margaret Green, David Lovell, C. Topham, George D. Stump, Helmout Modjtahedi	2005	56
8	Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer New England Journal of Medicine ·Thierry André, C. Boni, نبيل الحفناوى, Matilde Navarro, Josep Tabernero, Tamas Hickish, C. Topham, Marta Zaninelli, Philip R. Clingan, John Bridgewater, Isabelle Tabah-Fisch, Aimery de Gramont Hit paper breakdown →	2004	2694
9	Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy British Journal of Cancer ·Ian Chau, A. Norman, David Cunningham, Justin S. Waters, C. Topham, Gary Middleton, Mark Hill, Paul J. Ross, Gadaka M.A., Gail E. Stewart, J. Oates	2004	50
10	Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy Journal of Clinical Oncology ·G. Stewart, Ian Chau, A. Norman, Maria Sonia L. Silva, C. Topham, Gary Middleton, Rumaisha Aziza Siregar, Paul J. Ross, J. Oates, David Cunningham	2004	3
11	The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters International Journal of Oncology ·Sharadah Essapen, Hilary Thomas, Margaret Green, Liu Huo, Martin Cook, George D. Stump, C. Topham, Helmout Modjtahedi	2004	34
12	Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial The Lancet ·F.W. Bomhoff, S. Haack, DJ Kerr, I. Akbaba, Michel Seymour, C. Topham, C S McArdle, Dionne Cain, Ciccone Ds	2003	137
13	Oncosurgery: A new reality in metastatic colorectal carcinoma Seminars in Oncology ·C. Topham, René Adam	2002	20
14	Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer The Lancet ·David Cunningham, Seppo Pyrhönen, R.D. James, Cornelis J.A. Punt, Tamas Hickish, Reino Heikkilä, Tom Børge Johannesen, Hans Starkhammar, C. Topham, Lucile Awad, Christian Jacques, Patrice Herait Hit paper breakdown →	1998	973
15	Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer - a pilot study European Journal of Cancer Care ·C. Topham, Judith Moore	1997	15
16	Informal out-patient discussions with patients following surgery for large bowel cancer: are they beneficial? European Journal of Cancer Care ·C B Cryer, GAIL DOULTON, C. Topham, George D. Stump	1995	9
17	Informal out-patient discussions with patients following surgery for large bowel cancer: are they beneficial? European Journal of Cancer Care ·C B Cryer, GAIL DOULTON, C. Topham, George D. Stump	1995	5
18	Comparison of Single-Agent Epirubicin and 5-Fluorouracil / Epirubicin/Mitomycin in Patients with Advanced Adenocarcinoma of the Pancreas Oncology ·C. Topham, J. Glees, R. Charles Coombes	1993	10
19	Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas British Journal of Cancer ·C. Topham, J. Glees, Nigel S. B. Rawson, E. Woods, R. Charles Coombes	1991	22
20	Effect of nitrazepam, amylobarbitone sodium and placebo on the electroencephalogram of normal subjects Psychopharmacology ·Jan Volavka, C. R. B. Joyce, Michael J. Maloney, William J. Brawn, ILCA MENDES VALE, C. Topham, D. F. Scott	1969	8

About C. Topham

C. Topham is a scholar working on Oncology, Hepatology, Hematology, Pulmonary and Respiratory Medicine and Biochemistry, having authored 37 papers that have together received 6.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (22 papers), Cancer Treatment and Pharmacology (11 papers), Gastric Cancer Management and Outcomes (10 papers), Colorectal Cancer Surgical Treatments (9 papers), Colorectal and Anal Carcinomas (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Cancer therapeutics and mechanisms (4 papers) and Iron Metabolism and Disorders (3 papers). The work is most often cited by research in Oncology (5.7k citations), Hepatology (826 citations), Pathology and Forensic Medicine (1.3k citations), Pulmonary and Respiratory Medicine (1.6k citations) and Surgery (1.6k citations). C. Topham has collaborated with scholars based in United Kingdom, France and Spain. Frequent co-authors include Tamas Hickish, Matilde Navarro, C. Boni, Thierry André, Josep Tabernero, Aimery de Gramont, John Bridgewater, Philip R. Clingan, Marta Zaninelli and Isabelle Tabah-Fisch. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, The Lancet, International Journal of Oncology and Seminars in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact